Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Summary

Phase II study of neoadjuvant treatment with Gemcitabine, Tarceva and Oxaliplatin followed by chemotherapy with Tarceva and Gemcitabine in patients with pancreatic adenocarcinoma with borderline resectability. The primary objective is to determine the resectability rate of patients with pancreas adenocarcinoma with borderline resectability determined radiologically, treated with Gemcitabine, Tarceva and Oxaliplatin followed by radiotherapy with Gemcitabine and Tarceva.

Timeline

Start

2011-02-10

Primary completion

2012-12

Completion

2012-12

Outcome

Outcome not reported

Stopped (Enrollment): “Due to a low recruitment rate since start of recruitment period.”

Drugs

Indications